Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.


Highly Potent API (HPAPI) Manufacturing Facility, Bidar

Sai Life Sciences opens new High-Potency API Manufacturing facility at its Bidar Campus

• Designed and validated to handle high potent molecules less than 1 μg/m3 containment
• First commercial production batch has commenced

Sai Life Sciences, one of India’s fastest growing Contract Research, Development & Manufacturing Organizations (CRO-CDMO), today announced the opening of a new High-Potency API (HPAPI) manufacturing facility at its cGMP API Manufacturing campus in Bidar, India. The addition of this new facility expands the company’s expertise across HPAPI development and manufacturing, providing its customers with a streamlined pathway for NCE development.

Making the announcement, Krishna Kanumuri, CEO & Managing Director of Sai Life Sciences said, “In recent years, we have been seeing an increase in projects involving oncology drugs, thus creating a need for high-potency APIs. To better serve this growing need and leverage recent advancements in technology related to HPAPI manufacturing, we have created this new facility. The addition of latest generation HPAPI manufacturing to our facilities expands our capacity to serve the diverse needs of our customers.”

The new 16000 sq. ft. HPAPI block, located in the Bidar Manufacturing Campus of the company, has the following features:

  • Designed and validated to handle high potent molecules less than 1 μg/m3 containment
  • Inbuilt warehouse to store KSMs, intermediates and finished goods
  • Dedicated sampling / dispensing area with isolators with three independent streams to handle commercial scale batches
  • Reactors to handle multiple unit operations equipped with isolators and split butterfly valves (SBVs)
  • Powder processing and packing area with isolators; dedicated isolator train for Quality Control testing
  • Deactivation facility

Earlier in 2022, the company had opened its HPAPI Development facility at its Hyderabad R&D campus. Now, with the addition of the new HPAPI production facility in Bidar, the company is capable of handling of all aspects of the project life cycle spanning process development, analytical development, particle engineering, warehousing, pilot, scale up, sampling, QC, powder processing, effluent treatment, packing, transportation and stability services.

Over the past couple of years, the company has undergone an intense phase of transformation as part of its Sai Nxt initiative, executing investments of over US$120M in its capacity and operations, expanding into new geographies, growing its scientific talent base, and raising the overall bar for quality, compliance and performance.

Share article

More News


Sai Life Sciences releases its Sustainability Report 2023

Sai Life Sciences, a leading global Contract Research, Development & Manufacturing Organization (CRO/ CDMO), released its Sustainability Report 2022-2023. Developed in accordance with the Global Reporting Initiative (GRI) Universal Standards 2021 framework, the fourth edition of the Sustainability report is based on the theme ‘Steadfast on Sustainability,’ and it articulates the company’s commitment to sustainability […]
Read more


Sai Life Sciences augments DMPK capabilities to ace large-scale collaborations

To offer global big pharma clients cutting-edge, end-to-end drug metabolism and pharmacokinetics (DMPK) services, Sai Life Sciences, a global Contract Research, Development & Manufacturing Organization (CRO-CDMO), has expanded its DMPK capabilities. The expansion comprises the addition of 25,000 sq. ft. of state-of-the-art labs equipped with cutting-edge instrumentation enabling high-end automation. Complementing the expansion has been […]
Read more


Sai Life Sciences strengthens discovery leadership

Sai Life Sciences, a leading global contract research, development, and manufacturing organization, announces the addition of two seasoned professionals to its leadership team. Dr Atul Tiwari joins as Vice President – Discovery Strategy & Business, while Dr Santosh Kulkarni takes on the role of Vice President – Medicinal Chemistry. Their wealth of experience promises to […]
Read more


Sai Life Sciences wins Gold in Brandon Hall Group’s Excellence in Technology Awards

Sai Life Sciences won Gold in Brandon Hall Group’s Excellence in Technology Awards in the ‘Best Advance in Content Authoring Technology’ category. Sai Life Sciences was recognized for the use of UL Create Tool, an easy-to-use, cloud-based authoring tool from UL Solutions, for making the learning process seamless and effective for all. The company utilized […]
Read more


Sai Life Silver Jubilee year

Sai Life Sciences enters its Silver Jubilee year; surpasses vision of 25 commercial molecules by 2025

Sai Life Sciences entered its Silver Jubilee year with aplomb, surpassing its vision of supporting global innovator partners in bringing 25 new medicines to market by 2025. The company crossed this milestone two years ahead of schedule and is poised to sustain this momentum on the back of a strong portfolio of molecules at various […]
Read more